Genetic biomarker trumps tissue type in landmark oncology approval
Nature Reviews Drug Discovery 16, 447 (2017).
doi:10.1038/nrd.2017.128
Author: Asher Mullard
The FDA granted accelerated approval to Merck & Co.'s PD1 blocker pembrolizumab for all cancers with a specific genetic biomarker, regardless of which tissue type is involved. “This is an important first for the cancer community,” said the FDA's Richard Pazdur, acting director of the
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research